Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711649 | 1.00 | KMT2A (0.51) | KMT2AMEN1HTTSMN1; SMN2LMNA | |
| SCHEMBL1711654 | 1.00 | KMT2A (0.51) | KMT2AMEN1HTTSMN1; SMN2LMNA | |
| SCHEMBL28780200 | 0.85 | KMT2A (0.52) | KMT2AMEN1HTTSMN1; SMN2LMNA | |
| SCHEMBL16065593 | 0.83 | KMT2A (0.51) | KMT2AMEN1HTTSMN1; SMN2LMNA | |
| SCHEMBL11808068 | 0.83 | LMNA (0.42) | KMT2AMEN1HTTSMN1; SMN2LMNA | |
| SCHEMBL1068738 | 0.82 | KMT2A (0.50) | KMT2AMEN1HTTSMN1; SMN2LMNA | |
| SCHEMBL17202943 | 0.82 | KMT2A (0.50) | KMT2AMEN1HTTSMN1; SMN2LMNA | |
| SCHEMBL17202944 | 0.82 | KMT2A (0.50) | KMT2AMEN1HTTSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL1068734 | 0.81 | KMT2A (0.49) | KMT2AMEN1HTTSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL1068732 | 0.81 | KMT2A (0.49) | KMT2AMEN1HTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120225910-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110230445-A1 | Substituted Heteroaryls | PFIZER INC | 2011-09-22 | — | — | US | disclosed |
| EP-2344458-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Pfizer Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2010029461-A1 | HETEROARYLS AMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225910-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | KMT2A 2365/4885MEN1 3704/4885HTT 755/4885 |
| US-20110230445-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | KMT2A 2175/4885MEN1 3531/4885HTT 722/4885 |
| US-20100063063-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | KMT2A 2175/4885MEN1 3531/4885HTT 722/4885 |
| US-20130165452-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | KMT2A 2175/4885MEN1 3531/4885HTT 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.